A study was performed to determine whether canagliflozin can reduce the thickness of epicardial adipose tissue, that is associated with insulin resistance and is a risk factor for coronary artery disease. The results published in the Diabetology and Metabolic Syndrome journal showed that this drug decreased the epicardial adipose tissue thickness in patients with type 2 diabetes mellitus (from 9.3 ± 2.5 to 7.3 ± 2.0 mm). This effect is independent of its impact on lowering blood glucose, indicating that canagliflozin may be helpful in preventing cardiovascular complications in this patient population.